Dxcover Limited, the UK based clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, has raised GBP 7.5m in a Series A funding round led by Eos Advisory LLP, the UK based venture capital firm, with participation from Mercia Asset Management PLC, the UK based specialist asset manager, Scottish Enterprise, the UK based non-departmental public body of the Scottish Government, University of Strathclyde, the UK based public research university, SIS Ventures Limited, the UK based venture capital firm, Norcliffe Capital Limited, the UK based private investment company, and private investor Mark Bamforth. Dxcover has also secured a GBP 2.2m grant from the European Innovation Council.
Target – Clinspec Diagnostics limited
Buyer – Mercia Asset Management PLC
Buyer – Eos Advisory LLP
Buyer – Scottish enterprise
Buyer – University Of strathclyde
Buyer – Sis Ventures limited
Buyer – Norcliffe Capital limited
Buyer – Mark Bamforth (private investor)
Seller – Shareholders
